FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention proposes 4-pyridinyl-N-acyl-L-phenylalanines of the formula (I) wherein R1-R7 have values given in the invention claim. These compounds are inhibitors of VCAM-1 binding with cells expressing VLA-4 and therefore they are used in treatment of diseases with symptoms associated with binding VCAM-1 with cells expressing VLA-4, for example, chronic inflammatory diseases. Proposed compounds are used as a medicinal agent or a pharmaceutical composition in treatment of rheumatic arthritis, cerebrospinal sclerosis and asthma.
EFFECT: valuable medicinal properties of compounds.
51 cl, 3 tbl, 54 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVES OF THIOAMIDE AND PHARMACEUTICAL COMPOSITION | 2000 |
|
RU2245874C2 |
4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES AND PHARMACEUTICAL COMPOSITION | 2000 |
|
RU2266901C2 |
DERIVATIVES OF CARBOXYLIC ACIDS (VARIANTS), PHARMACEUTICAL COMPOSITION AND METHOD FO SELECTIVE BINDING αβ-INTEGRIN IN MAMMAL | 2000 |
|
RU2263109C2 |
HETEROCYCLIC DIHYDROPYRIMIDINE COMPOUNDS | 2000 |
|
RU2296766C2 |
1-HYDROXYIMINO-3-PHENYL-PROPANES | 2011 |
|
RU2579114C9 |
PHENYLALANINOLE DERIVATIVES | 2000 |
|
RU2238265C2 |
AMINOMETHYL QUINOLONES USEFUL IFOR TREATMENT OF JNK-MEDIATED DISORDER | 2012 |
|
RU2629111C2 |
PYRROLIDINE DERIVATIVES | 2010 |
|
RU2562605C2 |
NEW PIPERAZINE AMIDE DERIVATIVES | 2008 |
|
RU2454412C2 |
NOVEL HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2769507C1 |
Authors
Dates
2006-02-20—Published
2000-11-29—Filed